The accreditation covers liver health diagnostics, including Hepatotrack, a molecular diagnostic liquid biopsy that is predictive of acute liver rejection post-liver transplant.
LuminoDx has received accreditation from the accreditation committee of the College of American Pathologists (CAP) for its diagnostic testing facility following an on-site inspection, the San Diego-based company announced.
The accreditation confirms that the laboratory meets CAP’s standards for quality, accuracy, and patient safety in laboratory medicine. The facility joins CAP-accredited laboratories worldwide that have undergone the organization’s inspection process.
“Receiving CAP accreditation is a tremendous honor and a critical validation of our team’s dedication,” says Yipeng Wang, chief executive officer, in a release. “This accreditation demonstrates that LuminoDx operates at the highest level of precision and quality, giving our clinicians and patients complete confidence in the integrity of the diagnostic results we provide. It’s an assurance that we adhere to the global gold standard in laboratory practices.”
[RELATED: Blood Test Shows Superior Sensitivity for Early-Stage Liver Cancer Detection]
The CAP Laboratory Accreditation Program is recognized by the US federal government and is considered more stringent than the government’s own inspection program. The accreditation covers liver health diagnostics, including Hepatotrack, a molecular diagnostic liquid biopsy that is predictive of acute liver rejection post-liver transplant.
The company also provides services with Olink proteomics analysis, ELISA analysis, spatial biology with ELEMENT’s Aviti24 system, and laboratory test development.
Photo caption: Transplant surgeon
Photo credit: LuminoDx
